UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no gra...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Petrioli, R, Sabatino, M, Fiaschi, A I, Marsili, S, Pozzessere, D, Messinese, S, Correale, P, Civitelli, S, Tanzini, G, Tani, F, De Martino, A, Marzocca, G, Lorenzi, M, Giorgi, G, Francini, G
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2004
Témata:
Short Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409570/
https://ncbi.nlm.nih.gov/pubmed/14735168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601521
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky